University of Cambridge > Talks.cam > Cambridge Oncology Seminar Series > ‘Novel dual-action combination therapy enhances angiogenesis whilst reducing tumour growth and spread’

‘Novel dual-action combination therapy enhances angiogenesis whilst reducing tumour growth and spread’

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact Mala Jayasundera.

Hosts: Jacqui Shields/Sakari Vanharanta (Hutchison/MRC Research Centre)

Increasing chemotherapy delivery to tumors, whilst enhancing drug uptake and reducing side effects, is a primary goal of cancer research. In mouse and human cancer models in vivo, we show that co-administration of low dose Cilengitide and Verapamil, increases tumor angiogenesis, leakiness, blood flow and Gemcitabine delivery. This approach reduces tumor growth, metastasis and minimizes side effects whilst extending survival. At a molecular level, this strategy alters gemcitabine transporter and metabolizing enzyme expression levels, enhancing the potency of Gemcitabine within tumor cells in vivo and in vitro. Thus, the dual action of low dose Cilengitide, in vessels and tumor cells, improves chemotherapy efficacy. Overall, our data demonstrate that vascular promotion therapy is a novel means to improve cancer treatment.

This talk is part of the Cambridge Oncology Seminar Series series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.

 

© 2006-2017 Talks.cam, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity